Pfizer PFE underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

Pfizer Inc. (PFE) agreed to sell its remaining stake worth $3.3 billion in Haleon PLC (HLN), marking its exit from the UK-based consumer ...

Representative Julie Johnson (D-Texas) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 12th, the Representative disclosed that they had sold between $1,001 and $15,000 ...

Equities research analysts at Zacks Research reduced their Q2 2026 earnings per share (EPS) estimates for Pfizer in a report issued on Thursday, March 20th. Zacks Research analyst K. Shah now ...

The most recent trading session ended with Pfizer (PFE) standing at $25.60, reflecting a -0.43% shift from the previouse trading day's closing. This change was narrower than the S&P 500's daily loss ...

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025. The Dow Jones closed lower by ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... Morgan Stanley Research has increased its prediction for the global market for obesity medications from $77 billion ...

Asian shares are mixed after gains in technology stocks snapped Wall Street’s four-week losing streak. Investors are awaiting ...

When the stock market's major indexes ... Based on Wall Street's consensus earnings forecast for 2025, York Water is valued at a 25% discount to its average forward price-to-earnings (P/E ...

Pfizer stock, on the other hand ... Despite what PFE’s lackluster share price performance might suggest, it produced strong 2024 results with full year revenue growing by 6.7% to $63.6 billion.